Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII [3]

Haemophilia

Volumn 10, Issue 6, 2004, Pages 747-750

  Gruppo, Ralph A ^a   Brown, D ^b,d   Wilkes, M M ^c   Navickis, R J ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c Hygeia Associates   (United States)

^d Gulf States Hemophilia and Thrombophilia Center   (United States)

Author keywords

Factor VIII; Haemophilia A; Haemorrhage; Half life; Meta analysis; Protein engineering

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANALYTICAL ERROR; BLEEDING; BREAKTHROUGH BLEEDING; CLINICAL OBSERVATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPOTHESIS; LETTER; MEDICAL DECISION MAKING; META ANALYSIS; METHODOLOGY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SAMPLING; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

DATA INTERPRETATION, STATISTICAL; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMORRHAGE; HUMANS; META-ANALYSIS; PEPTIDE FRAGMENTS;

EID: 11144299535     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.01034.x     Document Type: Letter

References (20)

1. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia 2003; 9: 251-60.
2. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Meta-analysis of observational studies of full-length and B-domain-deleted factor VIII for prophylaxis - a standard statistical approach. Haemophilia 2003; 9: 748-50.
3. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII - a robust meta-analytic finding. Haemophilia DOI: 10. 1111/j.1365-2516.2004. 00931.x. Online publication date 1 July 2004.
4. Mikaelsson M. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - another rebuttal. Haemophilia 2004; 10: 305-7.
5. Berlin JA. Benefits of heterogeneity in meta-analysis of data from epidemiologic studies. Am J Epidemiol 1995; 142: 383-7.
6. Lusher JM, Kessler C, White GC et al. Routine prophylaxis treatment in previously treated patients (PTPs) with B-domain deleted recombinant FVIII (BDDrFVIII). Blood 2001; 98: 40a.
7. Schulman S, Kessler C, White G et al. Routine prophylaxis treatment in previously treated patients (PTPs) with B-domain deleted recombinant factor VIII (BDDrFVIII). Thromb Haemost 2001; 86: P1827.
8. Kessler C, Schulman S, White G et al. Routine prophylaxis treatment in previously treated patients (PTPs) with B-domain deleted recombinant factor VIII (BDDrFVIII). Presented at the National Hemophilia Foundation meeting, Nashville, Tennessee, November 15-17, 2001.
9. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program, Vol. 4. Atlanta, GA: US Department of Health and Human Services, 2002: 1-28.
10. Fijnvandraat K, Berntorp E, ten Cate JW et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77: 298-302.
11. Kessler C, Gill J, Spira J. Results of a three way crossover, randomized single blind pharmacokinetic study of rVIII SQ and pdFVIII patients with severe hemophilia A. Haemophilia 1998; 4: 188.
12. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998; 316: 61-6.
13. Tusell Puigbert J, Spira J. One-year use of recombinant factor VIII SQ (r-VIII SQ, Pharmacia, Sweden) in patients with haemophila A. Haemophilia 1996; 2 (Suppl. 1): 40.
14. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38: 44-51.
15. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78: 256-60.
16. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81 2925-35.
17. Eaton DL, Wood WI, Eaton D et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 1986; 25: 8343-7.
18. Meulien P, Faure T, Mischler F et al. A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII. Protein Eng 1988; 2: 301-6.
19. Wikén M, Sjöberg K. Analysis of samples from patients treated with ReFacto® for the presence of anti-SQ-peptide specific antibodies. Semin Thromb Hemost 2002; 28: 297-308.
20. Hanna WT, Zimmerman CE. Lack of adequate bleed prevention and FVIII activity recovery with Refacto®: a series of case studies in hemophilia A patients. Blood 2001; 98: 531a.